Physician profile
Lisette Hill
NPI 1043518707
$758.95
in general payments reported to CMS, 2019-2025
13 companies · $616 in 2025
The $616 reported for 2025 was more than what 94% of Pediatrics (Nurse Practitioner) providers received nationally (typical 2025 total: $93.49).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $14.73 · 2022: $108 · 2023: $20.54 · 2025: $616.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $636.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $636.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $289.59 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $134.88 | 2025 | Dupixent |
| Pfizer INC. | $64.09 | 2022-2025 | |
| Sanofi Pasteur INC. | $44.02 | 2022 | |
| Organon LLC | $41.72 | 2025 | Vtama |
| Amgen INC. | $29.32 | 2025 | Otezla |
| Merck Sharp & Dohme LLC | $28.74 | 2021-2022 | |
| Regeneron Pharmaceuticals, INC. | $27.99 | 2025 | Dupixent |
| Incyte Corporation | $24.73 | 2025 | Opzelura |
| Botanix Sb INC | $23.17 | 2025 | Sofdra |
| Arcutis Biotherapeutics, INC. | $22.25 | 2025 | Zoryve |
| Cranial Technologies, INC | $15.51 | 2022 | |
| Glaxosmithkline, LLC. | $12.94 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lisette Hill listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.